Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Chart Review Study to Describe the Real-world Outcomes and Use of Avelumab in Combination With Axitinib for Treatment of Patients With Advanced Renal Cell Carcinoma in the United Kingdom.

NCT05394493 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05394493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Chart Review Study to Describe the Real-world Outcomes and Use of Avelumab in Combination With Axitinib for Treatment of Patients With Advanced Renal Cell Carcinoma in the United Kingdom.
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 11, 2021
Completion date
August 30, 2023
Enrollment
130 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma